{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:33:34Z","timestamp":1781742814901,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40273-023-01347-7","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:36:44Z","timestamp":1706107004000},"page":"373-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-0374","authenticated-orcid":false,"given":"Clara","family":"Marquina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-5758","authenticated-orcid":false,"given":"Jedidiah I","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-5458","authenticated-orcid":false,"given":"Melanie","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-8617","authenticated-orcid":false,"given":"Dina","family":"Abushanab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0466-7385","authenticated-orcid":false,"given":"Yeji","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-7592","authenticated-orcid":false,"given":"Tamrat","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-8061","authenticated-orcid":false,"given":"Adam","family":"Livori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-3762","authenticated-orcid":false,"given":"Padam","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-1524","authenticated-orcid":false,"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-3522","authenticated-orcid":false,"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"3","key":"1347_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","volume":"30","author":"GF Watts","year":"2021","unstructured":"Watts GF, Sullivan DR, Hare DL, Kostner KM, Horton AE, Bell DA, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia\u2217. Heart Lung Circ. 2021;30(3):324\u201349.","journal-title":"Heart Lung Circ"},{"issue":"22","key":"1347_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease. Circulation. 2020;141(22):1742\u201359.","journal-title":"Circulation"},{"issue":"6","key":"1347_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jacl.2020.08.004","volume":"14","author":"Z Ademi","year":"2020","unstructured":"Ademi Z, Marquina C, Zomer E, Bailey C, Owen A, Pang J, et al. The economic impact of familial hypercholesterolemia on productivity. J Clin Lipidol. 2020;14(6):799-806.e3.","journal-title":"J Clin Lipidol"},{"issue":"13","key":"1347_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011822","volume":"8","author":"P Patel","year":"2019","unstructured":"Patel P, Hu Y, Kolinovsky A, Geng Z, Ruhl J, Krishnamurthy S, et al. Hidden burden of electronic health record-identified familial hypercholesterolemia: clinical outcomes and cost of medical care. J Am Heart Assoc. 2019;8(13): e011822.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1347_CR5","first-page":"303","volume":"62","author":"LR Araujo","year":"2018","unstructured":"Araujo LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Arch Endocrinol Metab. 2018;62(3):303\u20138.","journal-title":"Arch Endocrinol Metab."},{"key":"1347_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337: a2423.","journal-title":"BMJ"},{"issue":"4","key":"1347_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001795","volume":"3","author":"C Page","year":"2023","unstructured":"Page C, Zheng H, Wang H, Rai TS, O\u2019Kane M, Hart P, et al. A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK\u2019s NHS long term plan. PLOS Glob Public Health. 2023;3(4): e0001795.","journal-title":"PLOS Glob Public Health."},{"issue":"2","key":"1347_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","volume":"17","author":"S Singh","year":"2015","unstructured":"Singh S, Bittner V. Familial hypercholesterolemia\u2013epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):482.","journal-title":"Curr Atheroscler Rep"},{"key":"1347_CR9","unstructured":"Federation WH. Familial Hypercholesterolemia: country mapping survey\u2014preliminary analysis. World Heart Federation, FH Europe; 2022."},{"key":"1347_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, Hovingh GK, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries\u2014The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234\u201355.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1347_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","volume":"20","author":"GF Watts","year":"2023","unstructured":"Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023;20(12):845\u201369.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1347_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.ijcard.2013.01.280","volume":"167","author":"Z Ademi","year":"2013","unstructured":"Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013;167(6):2391\u20136.","journal-title":"Int J Cardiol"},{"key":"1347_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2022.06.1011","volume":"355","author":"B Jahn","year":"2022","unstructured":"Jahn B, Santamaria J, Dieplinger H, Binder CJ, Ebenbichler C, Scholl-B\u00fcrgi S, et al. Familial hypercholesterolemia: a systematic review of modeling studies on screening interventions. Atherosclerosis. 2022;355:15\u201329.","journal-title":"Atherosclerosis"},{"key":"1347_CR14","volume-title":"Methods for the economic evaluation of health care programmes","author":"MFS Drummond","year":"2015","unstructured":"Drummond MFS, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"6","key":"1347_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"2324","key":"1347_CR16","volume":"148","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy VL, Raatz H, et al. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Med Wkly. 2018;148(2324): w14626.","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"1347_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929\u201335.","journal-title":"Value Health."},{"issue":"7349","key":"1347_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/bmj.324.7349.1303","volume":"324","author":"D Marks","year":"2002","unstructured":"Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002;324(7349):1303.","journal-title":"BMJ"},{"issue":"6","key":"1347_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","volume":"177","author":"Z Ademi","year":"2023","unstructured":"Ademi Z, Norman R, Pang J, Sijbrands E, Watts GF, Hutten BA, et al. Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands. JAMA Pediatr. 2023;177(6):625\u201332.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"1347_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCGEN.122.003842","volume":"16","author":"C Marquina","year":"2023","unstructured":"Marquina C, Morton J, Brett T, Lloyd M, Radford J, Heal C, et al. Enhancing the detection and care of heterozygous familial hypercholesterolemia in primary care: cost-effectiveness and return on investment. Circ Genom Precis Med. 2023;16(3):267\u201374.","journal-title":"Circ Genom Precis Med."},{"issue":"34","key":"1347_CR21","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1093\/eurheartj\/ehab770","volume":"43","author":"C Marquina","year":"2022","unstructured":"Marquina C, Lacaze P, Tiller J, Riaz M, Sturm AC, Nelson MR, et al. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. Eur Heart J. 2022;43(34):3243\u201354.","journal-title":"Eur Heart J"},{"key":"1347_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.05.007","volume":"304","author":"Z Ademi","year":"2020","unstructured":"Ademi Z, Norman R, Pang J, Liew D, Zoungas S, Sijbrands E, et al. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment? Atherosclerosis. 2020;304:1\u20138.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1347_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","volume":"8","author":"Z Ademi","year":"2014","unstructured":"Ademi Z, Watts GF, Pang J, Sijbrands EJ, van Bockxmeer FM, O\u2019Leary P, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8(4):390\u2013400.","journal-title":"J Clin Lipidol"},{"issue":"14","key":"1347_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","volume":"97","author":"L Nherera","year":"2011","unstructured":"Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97(14):1175\u201381.","journal-title":"Heart"},{"issue":"23","key":"1347_CR25","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","volume":"38","author":"M Kerr","year":"2017","unstructured":"Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832\u20139.","journal-title":"Eur Heart J"},{"key":"1347_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","volume":"275","author":"AJ McKay","year":"2018","unstructured":"McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1\u20132 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis. 2018;275:434\u201343.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1347_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/jpm12030330","volume":"12","author":"M Jones","year":"2022","unstructured":"Jones M, Akyea RK, Payne K, Humphries SE, Abdul-Hamid H, Weng S, et al. Cost-effectiveness of screening algorithms for familial hypercholesterolaemia in primary care. J Pers Med. 2022;12(3):330.","journal-title":"J Pers Med."},{"issue":"24","key":"1347_CR28","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1053\/euhj.2002.3281","volume":"23","author":"PJ Marang-van-de-Mheen","year":"2002","unstructured":"Marang-van-de-Mheen PJ, ten Asbroek AH, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J. 2002;23(24):1922\u201330.","journal-title":"Eur Heart J"},{"issue":"1","key":"1347_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-2004-822992","volume":"4","author":"D Wonderling","year":"2004","unstructured":"Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med. 2004;4(1):97\u2013104.","journal-title":"Semin Vasc Med."},{"key":"1347_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.atherosclerosis.2018.05.021","volume":"275","author":"P Crosland","year":"2018","unstructured":"Crosland P, Maconachie R, Buckner S, McGuire H, Humphries SE, Qureshi N. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales. Atherosclerosis. 2018;275:80\u20137.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1347_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0300-8932(09)70021-1","volume":"62","author":"J Oliva","year":"2009","unstructured":"Oliva J, L\u00f3pez-Bastida J, Moreno SG, Mata P, Alonso R. Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. Rev Esp Cardiol. 2009;62(1):57\u201365.","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"1347_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","volume":"11","author":"P L\u00e1zaro","year":"2017","unstructured":"L\u00e1zaro P, P\u00e9rez-de-Isla L, Watts GF, Alonso R, Norman R, Mu\u00f1iz O, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260\u201371.","journal-title":"J Clin Lipidol"},{"key":"1347_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ijcard.2014.12.070","volume":"181","author":"CX Chen","year":"2015","unstructured":"Chen CX, Hay JW. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol. 2015;181:417\u201324.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1347_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacl.2022.07.014","volume":"16","author":"SJ Spencer","year":"2022","unstructured":"Spencer SJ, Jones LK, Guzauskas GF, Hao J, Williams MS, Peterson JF, et al. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. J Clin Lipidol. 2022;16(5):667\u201375.","journal-title":"J Clin Lipidol"},{"key":"1347_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.atherosclerosis.2018.01.036","volume":"270","author":"A Pelczarska","year":"2018","unstructured":"Pelczarska A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, My\u015bliwiec M, Grucha\u0142a M, et al. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland. Atherosclerosis. 2018;270:132\u20138.","journal-title":"Atherosclerosis"},{"key":"1347_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.vhri.2022.08.009","volume":"33","author":"MB Araujo","year":"2023","unstructured":"Araujo MB, Zerbino MC. Cost-effectiveness of pediatric universal screening for familial hypercholesterolemia in Argentina. Value Health Reg Issues. 2023;33:33\u201341.","journal-title":"Value Health Reg Issues."},{"issue":"3","key":"1347_CR37","first-page":"1","volume":"22","author":"O Health","year":"2022","unstructured":"Health O. Genetic testing for familial hypercholesterolemia: health technology assessment. Ont Health Technol Assess Ser. 2022;22(3):1\u2013155.","journal-title":"Ont Health Technol Assess Ser."},{"issue":"2","key":"1347_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jpc.15700","volume":"58","author":"AC Martin","year":"2022","unstructured":"Martin AC, Hooper AJ, Norman R, Nguyen LT, Burnett JR, Bell DA, et al. Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. J Paediatr Child Health. 2022;58(2):281\u20137.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"1347_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jama.2023.11330","volume":"330","author":"MJ Barry","year":"2023","unstructured":"Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker TR, Davis EM, et al. Screening for lipid disorders in children and adolescents: US preventive services task force recommendation statement. JAMA. 2023;330(3):253\u201360.","journal-title":"JAMA"},{"issue":"11","key":"1347_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002723","volume":"12","author":"C Lee","year":"2019","unstructured":"Lee C, Rivera-Valerio M, Bangash H, Prokop L, Kullo IJ. New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature. Circ Genom Precis Med. 2019;12(11): e002723.","journal-title":"Circ Genom Precis Med."},{"key":"1347_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2019.11.028","volume":"293","author":"DS Wald","year":"2020","unstructured":"Wald DS, Bestwick JP. Reaching detection targets in familial hypercholesterolaemia: comparison of identification strategies. Atherosclerosis. 2020;293:57\u201361.","journal-title":"Atherosclerosis"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01347-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:28:16Z","timestamp":1710361696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01347-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01347-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"17 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DA, YB, TA, AL and PD report no conflict of interest. CM, JIM, ML and ZA are authors in some of the studies included in this systematic review; no other conflict of interest. GFW reports honoraria for lectures and advisory boards or research grants from Amgen, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"CM contributed to study conceptualisation, quality appraisal, data extraction, and cost-adaptation processes and wrote the first manuscript. JD, ML, DA, TA, PD, AL and YB contributed to data extraction, quality appraisal and editing of the manuscript. GW contributed to the editing of the manuscript. ZA contributed to study conceptualisation, editing of the manuscript, supervision and is the study guarantor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Ethics approval was not required for this study as it relied on published and publicly available data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}